Cybin Therapeutics, shirkad gaar loo leeyahay oo ah daweynta bioscience oo ujeedadeedu tahay in ay ogaato oo ay horumariso hab-maamuuska daweynta ee caawiya psilocybin, ayaa PEX010 (25 mg) shati ka siisay Filament si loogu isticmaalo tijaabada. Tijaabada ayaa la filayaa inay ka bilaabato Q3'22 waxaana ku jiri doona shakhsiyaadka qaba xanuunka weyn ee niyad-jabka kuwaas oo qaadanaya daaweynta serotonin reuptake inhibitor (SSRI), oo caadi ahaan loo isticmaalo in lagu daweeyo niyad-jabka, iyo sidoo kale kuwa SSRI-naive.
"Oggolaanshaha caafimaadka Kanada ayaa marag u ah labadaba ansaxnimada tijaabadan iyo sidoo kale awoodda Filament ee soo saarista iyo shatiyeynta musharraxiinta dawada dhirta ee heerka-farmasiga," ayuu yiri Madaxa Sare ee Filament, Benjamin Lightburn. "Saamaynta daawaynta psilocybin ee bukaanada qaadanaya daawada dhaqameed ee antidepressant SSRI waa baaritaan aad muhiim u ah, waxaanan ku faraxsanahay inaan ka qayb qaadano cilmi-baaristan muhiimka ah."
"Qaar badan oo Kanadiyaanka ah oo la dagaallama niyad-jabka ayaa mara daaweynta SSRI, iyo ilaa hadda, tani waxay guud ahaan ka dhigan tahay in laga saaro tijaabooyinka daaweynta nafsiga ee caawiya maskaxda (PAP)," ayuu yiri Josh Taylor, Founder of Cybin Therapeutics. "Haddii la muujin karo in PAP si badbaado leh oo waxtar leh loo siin karo bukaannada SSRIs, qaar badan ayaa ka faa'iideysan doona. Waxaan dareensanahay in tani ay tahay fursad qaali ah oo aan ku tusno Caafimaadka Kanada in Cybin Therapeutics ay hagaajin karto natiijooyinka bukaannada kooxdayada iyo horumarinta borotokoollada."
Filament ayaa sidoo kale shati u siisay PEX010 (25 mg) CT si loogu daro marxaladda 2 ee tijaabooyinka bukaan-socodka, kuwaas oo la filayo inay bilaabaan rubuci afaraad ee 2022. Labada tijaaboba waxaa hogaamin doona Dr. Reg Peters iyo Dave Phillips.
